Synthetic and semi-synthetic acetyl-cholinesterase inhibitor agents (AChEIs) are clinically prescribed to patients who suffer from neurological disorders such as Alzheimer’s disease as a first step in the treatment process, but almost all of them showed some adverse secondary effects, mainly hepatotoxicity and gastric disturbances [1]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.